ReviewDrug design, development and therapy2025
Safety of Remimazolam in Vulnerable Populations.
Review in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Local Urticarial Reaction Above the Site of an Intravenous Cannula: Possible Allergy to Remimazolam in a Fourteen-Year-Old Adolescent.Journal of medical cases · 2026Article
- Emerging Sedation Strategies in Pediatric Emergency Care: Pharmacological Advances and Clinical Applications.Cureus · 2026Review
- Effect of remazolam combined with hydromorphone postoperative analgesia on cognitive function in elderly patients undergoing hip replacement.American journal of translational research · 2026Article
- Application value and safety advantages of remimazolam tosilate in sedation for emergency rescue endotracheal intubation.American journal of translational research · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vulnerable populations require careful consideration in drug selection due to their unique physiological conditions. Remimazolam, an innovative ultra-short-acting benzodiazepine, presents several advantages, including rapid onset, brief duration of action, and high predictability. Despite the extensive literature on remimazolam, few studies have specifically evaluated its safety in vulnerable patient populations. This review offers a comprehensive analysis of the safety profile of remimazolam in vulnerable populations, including cardiovascular diseases, neurological disorders, hepatic and renal dysfunction, respiratory conditions, metabolic disorders, rare diseases, and special groups such as the elderly and pediatric patients. It assesses recovery outcomes, hemodynamic stability, and adverse events such as respiratory depression and delirium. In our view, the prophylactic potential of remimazolam in these aspects may not be inferior to traditional anesthetic drugs (propofol, sevoflurane, etomidate, etc). and shows a trend of surpassing them in some aspects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.